Ascentage Pharma to Attend 3 Investor Conferences in October
Ticker: AAPG · Form: 6-K · Filed: Oct 7, 2025 · CIK: 2023311
Sentiment: neutral
Topics: conference-participation, foreign-private-issuer, press-release
TL;DR
Ascentage Pharma (001-42484) is hitting 3 investor conferences this October.
AI Summary
Ascentage Pharma Group International announced on October 7, 2025, that it will participate in three investor conferences during October 2025. The company, located at 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, China, is a foreign private issuer filing a Form 6-K.
Why It Matters
Company participation in investor conferences signals engagement with the financial community and potential for future investment or partnership discussions.
Risk Assessment
Risk Level: low — This filing is a routine announcement of conference participation and does not contain material financial or operational changes.
Key Numbers
- 3 — Investor Conferences (Ascentage Pharma's planned participation in upcoming events.)
Key Players & Entities
- Ascentage Pharma Group International (company) — Filer of the report
- October 7, 2025 (date) — Date of press release issuance
- October 2025 (date) — Period of investor conference participation
- 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, China (location) — Principal executive offices
- 001-42484 (company) — SEC Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed to furnish a press release announcing Ascentage Pharma Group International's participation in three upcoming investor conferences in October 2025.
When was the press release issued?
The press release was issued on October 7, 2025.
Where are Ascentage Pharma Group International's principal executive offices located?
The principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
What is the SEC Commission File Number for Ascentage Pharma Group International?
The SEC Commission File Number is 001-42484.
What type of annual report does Ascentage Pharma Group International file?
Ascentage Pharma Group International files its annual reports under cover of Form 20-F.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2025-10-07 09:15:24
Filing Documents
- ea0260527-6k_ascentage.htm (6-K) — 11KB
- ea026052701ex99-1_ascentage.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-096819.txt ( ) — 28KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On October 7, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated October 7, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: October 7, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3